



September 1, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Hidetoshi Segi, President and Representative Director
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL:06-6758-8223)

Notice Regarding the Status of Repurchase of Shares
(Repurchase of Shares pursuant to Provisions of Articles of Incorporation
in accordance with Article 459, Paragraph 1 of the Companies Act)

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces the status of its repurchase of shares pursuant to Article 459, Paragraph 1 of the Companies Act, as follows.

1. Class of Shares Repurchased	Common stock
2. Total Number of Shares Repurchased	595,400 shares
3. Total Repurchase Price	1,719,225,643 yen
4. Period of Repurchase	From August 7, 2026 to August 31, 2026
5. Repurchase Method	Market purchases on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the Board of Directors meeting held on March 26, 2026
 - (1) Class of Shares Repurchased Common stock
 - (2) Total Number of Shares Repurchased Up to 1,500,000 shares
(0.66% of total number of issued shares (excluding treasury stock))
 - (3) Total Repurchase Price Up to 3 billion yen
 - (4) Period of Repurchase From March 27, 2026 to December 31, 2026
 - (5) Repurchase Method Market purchases on the Tokyo Stock Exchange
2. Cumulative status of repurchase pursuant to the above Board of Directors resolution (as of August 31, 2026)
 - (1) Total Number of Shares Repurchased 595,400 shares
 - (2) Total Repurchase Price 1,719,225,643 yen